ADAGIO THERAPEUTICS INC (ADGI) Stock News

USA - NASDAQ:ADGI - US00534A1025 - Common Stock

4.64 USD

+0.04 (+0.87%)

Last: 9/12/2022, 8:13:11 PM

4.52 USD

-0.12 (-2.59%)

After Hours: 9/12/2022, 8:13:11 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

ADGI Latest News, Press Relases and Analysis

All

Press Releases

3 years ago - By: Kahn Swick & Foti, LLC - Mentions: IVVD

INVIVYD SHAREHOLDER ALERT by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Reminds Investors With Losses in Excess of $100,000 of Lead Plaintiff Deadline in Class Action Lawsuit Against Invivyd, Inc. – IVVD, ADGI

3 years ago - By: Rosen Law Firm - Mentions: IVVD

NATIONALLY RANKED ROSEN LAW FIRM Encourages Invivyd, Inc. f/k/a Adagio Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – IVVD, ADGI

4 years ago - By: Benzinga

Adagio Pauses FDA Emergency Use Request For Its COVID-19 Therapy

4 years ago - By: The Business Journals

News Image

The Petri Dish: Adagio says its antibody works against omicron now

3 years ago - By: Invivyd, Inc. - Mentions: IVVD

Invivyd Announces Multiple Next Generation COVID-19 Antibody Candidates and Selects Combination for Clinical Advancement Based on Positive in vitro Data Against Omicron Variants

3 years ago - By: Adagio Therapeutics, Inc. - Mentions: IVVD

Adagio Therapeutics Announces Corporate Name Change to Invivyd

3 years ago - By: Adagio Therapeutics, Inc.

Adagio Therapeutics to Participate in Upcoming Investor Conferences

3 years ago - By: Benzinga - Mentions: ADES KRBP GME ATNF ...

Why AMC Entertainment Is Trading Lower By 33%; Here Are 31 Stocks Moving Premarket

3 years ago - By: Adagio Therapeutics, Inc.

Adagio Therapeutics Reports Second Quarter 2022 Financial Results and Business Highlights

3 years ago - By: InvestorPlace - Mentions: DAVE PZN TEVA IMPP ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Wednesday

3 years ago - By: Mithril Capital Management LLC

Mithril Capital’s Ajay Royan Sends Letter Thanking Adagio Therapeutics Shareholders for Support of Successful Proxy Campaign

3 years ago - By: Adagio Therapeutics, Inc.

Adagio Announces David Hering Named Permanent Chief Executive Officer and Director

3 years ago - By: Adagio Therapeutics, Inc.

Adagio Announces Results of Annual Meeting of Stockholders and Evolution of the Board of Directors

4 years ago - By: Adagio Therapeutics, Inc.

Adagio Therapeutics Reports First Quarter 2022 Financial Results

4 years ago - By: Adagio Therapeutics, Inc.

Adagio Therapeutics Provides Update on Timing of Adintrevimab EUA Request

4 years ago - By: Adagio Therapeutics, Inc.

Adagio Therapeutics anuncia que ADG20 (adintrevimab) es el primer anticuerpo monoclonal que cumple con los principales criterios de valoración con importancia estadística en la profilaxis pre-exposición (PrEP) y profilaxis post-exposición (PEP).y

4 years ago - By: Adagio Therapeutics, Inc.

Adagio Therapeutics anuncia que o ADG20 (adintrevimabe) é o primeiro anticorpo monoclonal a atingir a meta final principal com significância estatística na profilaxia e tratamento pré e pós-exposição à COVID-19, e que pretende solicitar autorização de uso

4 years ago - By: Adagio Therapeutics, Inc.

Adagio Therapeutics Mengumumkan ADG20 (adintrevimab) adalah Antibodi Monoklonal Pertama untuk Memenuhi Titik Akhir Utama dengan Kepentingan Statistik Merentas Profilaksis dan Rawatan Pra dan Pos Pendedahan untuk COVID-19 dan Merancang untuk Mendapatkan

4 years ago - By: Adagio Therapeutics, Inc.

Adagio Therapeutics의 ADG20(adintrevimab), 1차 평가변수 충족한 최초의 단일 클론 항체로 코로나19 노출 전후 예방 및 치료에 있어 통계학적으로 유의미한 결과 보이며 미국에서 긴급사용승인 추진

4 years ago - By: Adagio Therapeutics, Inc.

アダジオ・セラピューティクス（Adagio Therapeutics）、ADG20（Adintrevimab）が新型コロナウイルスの暴露前後の予防と治療において統計的に有意な主要エンドポイントを満たす最初のモノクローナル抗体であり、米国の緊急使用許可を求める予定であると発表

4 years ago - By: Adagio Therapeutics, Inc.

Adagio Therapeutics gibt bekannt, dass ADG20 (Adintrevimab) der erste monoklonale Antikörper ist, der die primären Endpunkte der Prophylaxe vor und nach Exposition sowie der Behandlung von COVID-19 mit statistischer Signifikanz erreicht hat, und plant die

4 years ago - By: Adagio Therapeutics, Inc.

Adagio Therapeutics annonce que l'ADG20 (adintrevimab) est le premier anticorps monoclonal à répondre aux critères d'évaluation primaires ayant une importance statistique dans l'ensemble de la prophylaxie pré et post-exposition et du traitement pour la

4 years ago - By: Adagio Therapeutics, Inc.

Adagio Therapeutics 宣佈 ADG20（adintrevimab）是第一個滿足主要終點的單克隆抗體，在接觸 2019 冠狀病毒病前後的預防和治療中具有統計學意義，並計劃尋求美國緊急使用授權

4 years ago - By: InvestorPlace - Mentions: DRCT VYNT NAOV GERN ...

Top Penny Stocks Today: Why Are ADGI, DRCT, VYNT, NAOV, GERN and SNOA Rising Today?